テキサスにおける骨髄線維症の臨床試験
テキサス内の拠点で、骨髄線維症に関する20件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Texas Oncology PA Dallas Presbyterian Hospital, Dallas
- MD Anderson Cancer Center, Houston
- SCRI Texas Oncology Northeast Texas, Tyler
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07357727A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- The University of Texas, MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Baylor University Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07623161Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- MD Anderson, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06343805High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/16更新 · NCT06345495A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07441694Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT07128381Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/26更新 · NCT06327100Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/20更新 · NCT06517875A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Md Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/17更新 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- MD Anderson, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/12更新 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UT - SouthWestern, Dallas
- U.T. MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at San Antonio, San Antonio
被験者募集中第3相
18歳以上 · 全性別 · 2025/09/25更新 · NCT06479135Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/13更新 · NCT05423691Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2023/02/21更新 · NCT05280509ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。